Document is current

Article History

Received: 29 March 2018

Revised: 13 August 2018

Accepted: 16 August 2018

First Online: 10 September 2018

Competing interests

: B.S. has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, Meda, Novartis and Teva, and has served on advisory boards arranged by AstraZeneca, Novartis, Meda, GlaxoSmithKline, Teva and Boehringer Ingelheim. K.K., J.-B.G., and F.S.G. are employed by Novartis Pharma AG, Basel, Switzerland. C.J. has received honoraria for educational activities and lectures from Novartis, AstraZeneca, GlaxoSmithKline, TEVA and Boehringer Ingelheim outside the submitted work. G.J. has participated in the steering committee by Novartis for this study and served on advisory boards arranged by AstraZeneca, Novo Nordisk, and Takeda. K.L. has, during the last 5 years, on one or more occasion served in an advisory board and/or served as speaker and/or participated in education arranged by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Orion, Novartis, TEVA and Takeda. L.J. and M.U. are employed by IQVIA. K.L. has received payments for educational activities and lectures from AstraZeneca, GlaxoSmithKline, Meda, MSD, Novartis and Nycomed, served on advisory boards arranged by Novartis and Meda, and has participated in the steering committee by Novartis for this study.